PROCHLORPERAZINE (*Stemetil*) (C)
(Revised: November 2015)

<table>
<thead>
<tr>
<th>TYPE:</th>
<th>Phenothiazine antiemetic [S4]</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRESENTATIONS:</td>
<td>12.5mg in 1ml – ampoule</td>
</tr>
</tbody>
</table>

**ACTIONS:**
Acts on several neurotransmitter systems:
1. antidopamine action
2. alpha-adrenergic antagonism
3. potentiates noradrenaline
4. weak anticholinergic and antihistamine effects
5. weak serotonin antagonism

Onset IM: limited data.
Duration IM: limited data – likely to be prolonged.

**USE:**

<table>
<thead>
<tr>
<th>ICP</th>
<th>AP</th>
</tr>
</thead>
<tbody>
<tr>
<td>For the treatment (only) of nausea and vomiting from a variety of vestibular causes, including: motion sickness, migraine, vertigo and labyrinthitis</td>
<td></td>
</tr>
</tbody>
</table>

**ADVERSE EFFECTS:**

- **Gastrointestinal:** constipation, dry mouth
- **Nervous system:** drowsiness, extrapyramidal symptoms
- **Cardiovascular:** hypotension, ECG changes (especially QT prolongation)
- **Respiratory:** respiratory depression

**CONTRAINDICATIONS:**
- Known hypersensitivity to phenothiazines
- CNS depression
- Shock from any cause, or other circulatory compromise
- Not for use in pregnancy
- Paediatric patients (<18 years old)
- Not to be given in conjunction with intravenous amiodarone
- Previous oral prochlorperazine within last 8 hours

*continues over*
PROCHLORPERAZINE (*Stemetil*) (C) – cont.

**PRECAUTIONS:**

1. Renal dysfunction
2. Parkinson’s disease
3. Myasthenia gravis
4. Epilepsy
5. Caution in elderly – increased risk of dystonic reactions

**DOSES:**

**ADULT:**

<table>
<thead>
<tr>
<th>ICP</th>
<th>12.5mg deep IMI.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><em>Single dose only.</em></td>
</tr>
</tbody>
</table>

**PAEDIATRIC (<18 years old):**

Not used.

**SPECIAL NOTE:**

Patients who are administered prochlorperazine are not to be left at home, due to extensive adverse effect profile, potential symptom masking and extended half-life of the drug.